10-Q: Oaktree Acquisition III Reports Q3 2025 Net Income, Faces Going Concern Doubt

Oaktree Acquisition Corp. III Life Sciences reported a net income of $1.97 million for Q3 2025, driven by trust account interest, but faces substantial doubt about its ability to continue as a going concern.

Summary

• Reported net income of $1,966,742 for the three months ended September 30, 2025, and $5,499,876 for the nine months ended September 30, 2025.
• Interest earned on cash held in the Trust Account was $2,192,321 for the three months and $6,440,067 for the nine months ended September 30, 2025.
• General and administrative expenses were $225,579 for the three months and $940,191 for the nine months ended September 30, 2025.
• Cash held in the Trust Account increased to $199,769,089 as of September 30, 2025, from $193,579,022 as of December 31, 2024.
• The company has until October 25, 2026, to complete a Business Combination.
• Management identified substantial doubt about the company's ability to continue as a going concern due to significant costs and the potential need for additional capital.
• Key management changes include the appointment of David A. Berry as an independent director and George A. Martinez as the new Chief Financial Officer, replacing Thomas Sweeney.

Sentiment

Score: 5

Explanation: The company reported positive net income driven by interest on its trust account, which is a positive for a SPAC. However, the explicit 'going concern' warning and the lack of an identified business combination target introduce significant uncertainty and risk, balancing the positive financial performance.

Positives

• Generated net income of $1,966,742 for the three months ended September 30, 2025, and $5,499,876 for the nine months ended September 30, 2025.
• Significant interest income of $2,192,321 for the quarter and $6,440,067 year-to-date from the Trust Account.
• Cash held in the Trust Account has grown to $199,769,089, providing substantial capital for a potential Business Combination.
• Appointment of an independent director, David A. Berry, MD, PhD, to the board and key committees (Audit, Nominating, Compensation).

Negatives

• Incurred a net loss of $48,095 for the three months ended September 30, 2024, and the period from inception through September 30, 2024.
• Accumulated deficit increased to $(6,765,200) as of September 30, 2025, from $(6,075,009) as of December 31, 2024.
• Net cash used in operating activities was $278,203 for the nine months ended September 30, 2025.
• The company has not yet identified a specific Business Combination target.
• Substantial doubt exists about the company's ability to continue as a going concern due to significant ongoing costs and the potential need for additional capital.
• The Sponsor's indemnification obligations are limited, and its only assets are company securities, raising concerns about its ability to satisfy these obligations.

Risks

• No operating history or revenues, making it difficult to evaluate the ability to achieve business objectives.
• Uncertainty in selecting and completing an appropriate target business or businesses.
• Risks associated with the performance of a prospective target business.
• Challenges in retaining or recruiting officers, key employees, or directors post-Business Combination.
• Potential conflicts of interest due to officers and directors allocating time to other businesses.
• Difficulty in obtaining additional financing to complete a Business Combination.
• The size and quality of the pool of prospective target businesses.
• Potential for significant redemptions by public shareholders, which could materially adversely affect the amount held in the Trust Account.
• General economic and political conditions, including recessions, interest rates, international currency fluctuations, health epidemics, inflation, changes in diplomatic and trade relationships, and acts of war or terrorism (specifically mentioning the Russia/Ukraine conflict and the Middle East conflict), could impact the ability to consummate a Business Combination.
• The Trust Account is not subject to claims of third parties, but the Sponsor's ability to indemnify the Trust Account is limited.
• Warrants will expire worthless if a Business Combination is not consummated within the Combination Period.

Future Outlook

The company expects to continue incurring significant costs in pursuit of its acquisition plans and will not generate operating revenues until after the completion of its initial Business Combination. It anticipates generating non-operating income from interest on the Trust Account. The company has until October 25, 2026, to consummate a Business Combination, and may need to raise additional capital to meet working capital needs, though there is no assurance of success in obtaining such financing.

Management Comments

• "We have neither engaged in any operations nor generated any revenues to date."
• "We do not expect to generate any operating revenues until after the completion of our business combination."
• "We expect to continue to incur significant costs in the pursuit of our acquisition plans."
• "Our officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company’s working capital needs."
• "Mr. Sweeneys resignation was not the result of any disagreements with the Board or management of the Company and he is resigning to pursue other professional opportunities."

Industry Context

As a Special Purpose Acquisition Company (SPAC) in the life sciences sector, Oaktree Acquisition Corp. III Life Sciences is currently in the pre-Business Combination phase, focused solely on identifying and acquiring a target company. Its financial performance is primarily driven by interest income from its Trust Account, which is typical for SPACs before an acquisition. The broader industry context for SPACs involves a competitive landscape for attractive targets and increasing regulatory scrutiny. The company's ability to find a suitable life sciences target within its timeframe will determine its success, against a backdrop of global economic uncertainties and geopolitical tensions that could affect M&A activity and financing conditions.

Comparison to Industry Standards

• NA (As a blank check company, Oaktree Acquisition Corp. III Life Sciences has no operating history or revenue-generating activities to compare against industry-specific operational benchmarks or competitors' project results. Its financial performance is limited to managing its Trust Account and incurring administrative expenses, which is standard for SPACs in the pre-combination phase.)

Management Changes

Corporate Governance

Related Party Transactions

• The Sponsor purchased 583,981 Private Placement Units for an aggregate of $5,839,810.
• A promissory note for $11,824 is outstanding to the Sponsor, which was originally from Oaktree Acquisition Holdings III LS, L.P.
• The company pays the Sponsor $25,000 per month for administrative services, totaling $75,000 for the three months and $225,000 for the nine months ended September 30, 2025.
• The company has an administrative services and indemnification agreement with the Sponsor, indemnifying the Sponsor and its affiliates (including Oaktree Capital Management, L.P.) from certain liabilities, with the caveat that indemnified parties cannot access Trust Account funds.
• The Sponsor or its affiliates/officers/directors may provide Working Capital Loans, up to $1.5 million of which could be convertible into private placement units.

Stakeholder Impact

• Shareholders: Public shareholders face the risk of warrants expiring worthless if no Business Combination occurs. They also face potential dilution if Working Capital Loans are converted into units. The value of their redeemable Class A shares is tied to the Trust Account, which is generating interest.
• Sponsor: The Sponsor has invested in Private Placement Units and holds Founder Shares, aligning its interests with completing a Business Combination. It also provides administrative services and may provide loans, but its indemnification capacity is limited to its holdings in the company.
• Underwriters: Entitled to a deferred underwriting fee of $6,719,660, payable only upon the completion of a Business Combination.
• Employees/Management: The recent CFO change indicates ongoing management adjustments. The ability to retain or recruit key personnel post-Business Combination is a risk.

Next Steps

• Identify and evaluate target businesses for a Business Combination.
• Perform business due diligence on prospective target businesses.
• Structure, negotiate, and complete a Business Combination by October 25, 2026.
• Potentially seek shareholder approval to extend the Combination Period if a Business Combination is not consummated by the deadline.
• File a registration statement covering Class A ordinary shares issuable upon exercise of warrants as soon as practicable, but no later than 20 business days after the closing of the initial Business Combination.

Key Dates

Recommendation

While the company reported positive net income from trust account interest, which is typical for a SPAC, the explicit 'going concern' warning and the absence of an identified Business Combination target introduce significant uncertainty. The company has a limited timeframe to complete an acquisition, and failure to do so would result in liquidation and warrants expiring worthless. The management changes are standard for a SPAC in this phase. Investors should hold, awaiting concrete developments regarding a Business Combination target and a clear path to resolving the going concern issue, as the current state presents both the potential for a successful acquisition and the risk of liquidation.

Keywords

SPAC, Blank Check Company, Oaktree Acquisition Corp. III Life Sciences, 10-Q, Quarterly Report, Financial Results, Trust Account, Business Combination, IPO, Warrants, Going Concern, SEC Filing, Life Sciences, Corporate Governance, Management Change, Financial Performance, Risk Factors